Bristol Myers Squibb stock faces a lower target after downgrade

Published on 10/06/2026 at 17:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock traded at USD 59.32 on October 6, 2026, while Leerink cut its target to USD 59 a day earlier. Q2 revenue reached USD 12.97 billion, up 5.7 percent year over year.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock was trading at USD 59.32 on the NYSE on October 6, 2026, at 11:48 a.m. ET, up 0.87 percent from the prior close of USD 58.81. The immediate catalyst was Leerink Partners' downgrade to Market Perform and its lower price target, according to Markets Insider on October 5, 2026.

Leerink cuts target to USD 59

Leerink reduced its rating from Outperform to Market Perform and cut the target from USD 73 to USD 59. The change followed a reassessment of several late-stage pipeline programs, including admilparant, milvexian and Cobenfy, Markets Insider reported.

The lower target sits 0.5 percent below the October 6 intraday price. That narrow gap contrasts with the broader analyst view, which still assigns Bristol Myers Squibb a Moderate Buy consensus rating and an average target of USD 67 from 25 analysts, according to MarketBeat on October 5, 2026. That average target lies 12.9 percent above the stock price.

Quarterly earnings set the benchmark

Bristol Myers Squibb reported USD 12.97 billion in second-quarter 2026 revenue, up 5.7 percent from the prior-year quarter. Quarterly EPS reached USD 2.04 against a USD 1.60 consensus estimate, a USD 0.44 beat, according to MarketBeat.

The earnings profile explains the split in the stock debate. Revenue growth provides a current operating comparison, while Leerink's concerns center on whether future pipeline launches can offset pressure from patent expirations affecting older medicines.

October 29 results are next

Bristol Myers Squibb will announce third-quarter 2026 results on October 29, 2026, followed by an 8:00 a.m. ET conference call, according to the company's release on Bristol Myers Squibb. The date gives investors a defined checkpoint for revenue growth, earnings delivery and pipeline commentary.

Stock trades below yearly high

Bristol Myers Squibb was last at USD 59.32 on the NYSE on October 6, 2026, with a 52-week range of USD 42.52 to USD 68.64, market capitalization of USD 121.2 billion and volume of 2,790,257 shares. The stock therefore stood 13.6 percent below its 52-week high.